The role of ANGPTL3 in controlling lipoprotein metabolism

被引:0
作者
Anna Tikka
Matti Jauhiainen
机构
[1] National Institute for Health and Welfare. Genomics and Biomarkers Unit,
[2] Biomedicum,undefined
来源
Endocrine | 2016年 / 52卷
关键词
Triglycerides; Lipoprotein metabolism; ANGPTL3; FHBL2; LPL;
D O I
暂无
中图分类号
学科分类号
摘要
Angiopoietin-like protein 3 (ANGPTL3) is a secretory protein regulating plasma lipid levels via affecting lipoprotein lipase- and endothelial lipase-mediated hydrolysis of triglycerides and phospholipids. ANGPTL3-deficiency due to loss-of-function mutations in the ANGPTL3 gene causes familial combined hypobetalipoproteinemia (FHBL2, OMIM # 605019), a phenotype characterized by low concentration of all major lipoprotein classes in circulation. ANGPTL3 is therefore a potential therapeutic target to treat combined hyperlipidemia, a major risk factor for atherosclerotic coronary heart disease. This review focuses on the mechanisms behind ANGPTL3-deficiency induced FHBL2.
引用
收藏
页码:187 / 193
页数:6
相关论文
共 50 条
  • [21] Hepatic fat changes with antisense oligonucleotide therapy targeting ANGPTL3
    Zimerman, Andre
    Wiviott, Stephen D.
    Park, Jeong-Gun
    Murphy, Sabina A.
    Ran, Xinhui
    Bramson, Candace R.
    Curto, Madelyn
    Ramos, Vesper
    Jevne, Alexandra
    Kuder, Julia F.
    Verma, Subodh
    Wojakowski, Wojtek
    Terra, Steven G.
    Sabatine, Marc S.
    Bergmark, Brian A.
    Marston, Nicholas A.
    JOURNAL OF CLINICAL LIPIDOLOGY, 2024, 18 (02) : e261 - e268
  • [22] ANGPTL3 Downregulation Increases Intracellular Lipids by Reducing Energy Utilization
    Pennisi, Grazia
    Maurotti, Samantha
    Ciociola, Ester
    Jamialahmadi, Oveis
    Bertolazzi, Giorgio
    Mirarchi, Angela
    Bergh, Per-Olof
    Scionti, Francesca
    Mancina, Rosellina M.
    Spagnuolo, Rocco
    Tripodo, Claudio
    Boren, Jan
    Petta, Salvatore
    Romeo, Stefano
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2024, 44 (05) : 1086 - 1097
  • [23] Variable Changes of Circulating ANGPTL3 and ANGPTL4 in Different Obese Phenotypes: Relationship with Vasodilator Dysfunction
    Schinzari, Francesca
    Vizioli, Giuseppina
    Campia, Umberto
    Tesauro, Manfredi
    Cardillo, Carmine
    BIOMEDICINES, 2021, 9 (08)
  • [24] ANGPTL3 serum concentration and rare genetic variants in Finnish population
    Tikka, Anna
    Metso, Jari
    Jauhiainen, Matti
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2017, 77 (08) : 601 - 609
  • [25] Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia
    Kosmas, Constantine E.
    Bousvarou, Maria
    Sourlas, Andreas
    Papakonstantinou, Evangelia J.
    Genao, Edilberto Pella
    Uceta, Rogers Echavarria
    Guzman, Eliscer
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2022, 14 : 49 - 59
  • [26] Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3
    Blackburn, Nicholas B.
    Meikle, Peter J.
    Peralta, Juan M.
    Kumar, Satish
    Leandro, Ana C.
    Bellinger, Melissa A.
    Giles, Corey
    Huynh, Kevin
    Mahaney, Michael C.
    Goring, Harald H. H.
    VandeBerg, John L.
    Williams-Blangero, Sarah
    Glahn, David C.
    Duggirala, Ravindranath
    Blangero, John
    Michael, Laura F.
    Curran, Joanne E.
    CIRCULATION-GENOMIC AND PRECISION MEDICINE, 2021, 14 (03): : 369 - 378
  • [27] ANGPTL3 as a target for treating lipid disorders in type 2 diabetes patients
    Chen, Jingfei
    Luo, Qin
    Yi, Yanfeng
    Wang, Jiangang
    Chen, Pengfei
    Luo, Fei
    Fang, Zhenfei
    LIPIDS IN HEALTH AND DISEASE, 2024, 23 (01)
  • [28] ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
    Akoumianakis, Ioannis
    Zvintzou, Evangelia
    Kypreos, Kyriakos
    Filippatos, Theodosios D.
    CURRENT ATHEROSCLEROSIS REPORTS, 2021, 23 (05)
  • [29] ANGPTL3 and ApoC-III inhibitors for treating hypertriglyceridemia in context: horses for courses?
    Chan, Dick C.
    Watts, Gerald F.
    CURRENT OPINION IN LIPIDOLOGY, 2024, 35 (03) : 101 - 109
  • [30] ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
    Ioannis Akoumianakis
    Evangelia Zvintzou
    Kyriakos Kypreos
    Theodosios D. Filippatos
    Current Atherosclerosis Reports, 2021, 23